Macro- and Microstructural White Matter Differences in Neurologic Postacute Sequelae of SARS-CoV-2 Infection

References

1. 1.↵
   1. Taquet M,
   2. Geddes JR,
   3. Husain M, et al

   . 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021;8:416–27 doi:10.1016/S2215-0366(21)00084-5 pmid:33836148

   CrossRefPubMed
2. 2.↵
   1. Thaweethai T,
   2. Jolley SE,
   3. Karlson EW

   ; RECOVER Consortium, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023;329:1934–46 doi:10.1001/jama.2023.8823 pmid:37278994

   CrossRefPubMed
3. 3.↵
   1. Schou TM,
   2. Joca S,
   3. Wegener G, et al

   . Psychiatric and neuropsychiatric sequelae of COVID-19—a systematic review. Brain Behav Immun 2021;97:328–48 doi:10.1016/j.bbi.2021.07.018 pmid:34339806

   CrossRefPubMed
4. 4.↵
   1. Taquet M,
   2. Sillett R,
   3. Zhu L, et al

   . Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022;9:815–27 doi:10.1016/S2215-0366(22)00260-7 pmid:35987197

   CrossRefPubMed
5. 5.↵
   1. Filley CM

   . White matter dementia. Ther Adv Neurol Disord 2012;5:267–77doi:10.1177/1756285612454323 pmid:22973423

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Filley CM

   . The behavioral neurology of cerebral white matter. Neurology 1998;50:1535–40 doi:10.1212/wnl.50.6.1535 pmid:9633691

   Abstract/FREE Full Text
7. 7.↵
   1. Gibson EM,
   2. Nagaraja S,
   3. Ocampo A, et al

   . Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 2019;176:43–55.e13 doi:10.1016/j.cell.2018.10.049 pmid:30528430

   CrossRefPubMed
8. 8.↵
   1. Schmahmann JD,
   2. Smith EE,
   3. Eichler FS, et al

   . Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci 2008;1142:266–309 doi:10.1196/annals.1444.017 pmid:18990132

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Kinnunen KM,
   2. Greenwood R,
   3. Powell JH, et al

   . White matter damage and cognitive impairment after traumatic brain injury. Brain 2011;134:449–63 doi:10.1093/brain/awq347 pmid:21193486

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Ungvari Z,
    2. Toth P,
    3. Tarantini S, et al

    . Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol 2021;17:639–54 doi:10.1038/s41581-021-00430-6 pmid:34127835

    CrossRefPubMed
11. 11.↵
    1. van Velzen LS,
    2. Kelly S,
    3. Isaev D, et al

    . White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. Mol Psychiatry 2020;25:1511–25 doi:10.1038/s41380-019-0477-2 pmid:31471575

    CrossRefPubMed
12. 12.↵
    1. Hickie I,
    2. Scott E,
    3. Wilhelm K, et al

    . Subcortical hyperintensities on magnetic resonance imaging in patients with severe depression–a longitudinal evaluation. Biol Psychiatry 1997;42:367–74 doi:10.1016/S0006-3223(96)00363-0 pmid:9276077

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Catani M,
    2. Ffytche DH

    . The rises and falls of disconnection syndromes. Brain 2005;128:2224–39 doi:10.1093/brain/awh622 pmid:16141282

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Radmanesh A,
    2. Derman A,
    3. Lui YW, et al

    . COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology 2020;297:e223–27 doi:10.1148/radiol.2020202040 pmid:32437314

    CrossRefPubMed
15. 15.↵
    1. Wang Y,
    2. Wang Y,
    3. Huo L, et al

    . SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature. J Neurol 2022;269:1071–92 doi:10.1007/s00415-021-10771-8 pmid:34459986

    CrossRefPubMed
16. 16.↵
    1. Klironomos S,
    2. Tzortzakakis A,
    3. Kits A, et al

    . Nervous system involvement in coronavirus disease 2019: results from a retrospective consecutive neuroimaging cohort. Radiology 2020;297:e324–34 doi:10.1148/radiol.2020202791 pmid:32729812

    CrossRefPubMed
17. 17.↵
    1. Marcic L,
    2. Marcic M,
    3. Kojundzic SL, et al

    . Personalized approach to patient with MRI brain changes after SARS-CoV-2 infection. J Pers Med 2021;11:442 doi:10.3390/jpm11060442

    CrossRefPubMed
18. 18.↵
    1. Gershon RC,
    2. Lai JS,
    3. Bode R, et al

    . Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res 2012;21:475–86 doi:10.1007/s11136-011-9958-8 pmid:21874314

    CrossRefPubMed
19. 19.↵
    1. Radloff LS

    . The CES-D scale: a self-report depression scale for research in the general population. App Psychol Meas 1977;1:385–401 doi:10.1177/014662167700100306

    CrossRef
20. 20.↵
    1. Phetsouphanh C,
    2. Darley DR,
    3. Wilson DB, et al

    . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022;23:210–16 doi:10.1038/s41590-021-01113-x pmid:35027728

    CrossRefPubMed
21. 21.↵
    1. Schultheiß C,
    2. Willscher E,
    3. Paschold L, et al

    . The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022;3:100663 doi:10.1016/j.xcrm.2022.100663 pmid:35732153

    CrossRefPubMed
22. 22.↵
    1. Rau A,
    2. Schroeter N,
    3. Blazhenets G, et al

    . Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms. Brain 2022;145:3203–13 doi:10.1093/brain/awac045 pmid:35675908

    CrossRefPubMed
23. 23.↵
    1. Soriano JB,
    2. Murthy S,
    3. Marshall JC

    , WHO Clinical Case Definition Working Group on Post-COVID-19 Condition, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102–07 doi:10.1016/S1473-3099(21)00703-9 pmid:34951953

    CrossRefPubMed
24. 24.↵
    1. Swartz MD,
    2. DeSantis SM,
    3. Yaseen A, et al

    . Antibody duration after infection from SARS-CoV-2 in the Texas coronavirus antibody response survey. J Infect Dis 2023;227:193–201 doi:10.1093/infdis/jiac167 pmid:35514141

    CrossRefPubMed
25. 25.↵
    1. Gaser C,
    2. Dahnke R,
    3. Thompson PM, et al

    . CAT–a computational anatomy toolbox for the analysis of structural MRI data. Gigascience 2024;13:giae049

    CrossRefPubMed
26. 26.↵
    1. O’Connor EE,
    2. Zeffiro TA,
    3. Lopez OL, et al

    . Differential effects of an AIDS defining illness and chronic HIV infection on gray matter volume. Clin Infect Dis 2021;73:e2303–107 doi:10.1093/cid/ciaa1552 pmid:33053187

    CrossRefPubMed
27. 27.↵
    1. Dhiman S,
    2. Hickey RE,
    3. Thorn KE, et al

    . PyDesigner v1.0: a pythonic implementation of the DESIGNER pipeline for diffusion magnetic resonance imaging. J Vis Exp 2024;207. doi:10.3791/66397

    CrossRef
28. 28.↵
    1. Fazekas F,
    2. Chawluk JB,
    3. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Ding T,
    2. Cohen AD,
    3. O’Connor EE, et al

    . An improved algorithm of white matter hyperintensity detection in elderly adults. Neuroimage Clin 2020;25:102151 doi:10.1016/j.nicl.2019.102151 pmid:31927502

    CrossRefPubMed
30. 30.↵
    1. Mori S,
    2. Oishi K,
    3. Jiang H, et al

    . Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. NeuroImage 2008;40:570–82 doi:10.1016/j.neuroimage.2007.12.035 pmid:18255316

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Jensen JH,
    2. Helpern JA,
    3. Ramani A, et al

    . Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med 2005;53:1432–40 doi:10.1002/mrm.20508 pmid:15906300

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Jensen JH,
    2. Helpern JA

    . MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010;23:698–710 doi:10.1002/nbm.1518 pmid:20632416

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Low RN,
    2. Low RJ,
    3. Akrami A

    . A review of cytokine-based pathophysiology of long COVID symptoms. Front Med (Lausanne) 2023;10:1011936 doi:10.3389/fmed.2023.1011936 pmid:37064029

    CrossRefPubMed
34. 34.↵
    1. Ho ML,
    2. Rojas R,
    3. Eisenberg RL

    . Cerebral edema. AJR Am J Roentgenol 2012;199:W258–73 doi:10.2214/AJR.11.8081 pmid:22915416

    CrossRefPubMed
35. 35.↵
    1. de Melo GD,
    2. Perraud V,
    3. Alvarez F, et al

    . Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. Nat Commun 2023;14:4485 doi:10.1038/s41467-023-40228-7 pmid:37495586

    CrossRefPubMed
36. 36.↵
    1. Besteher B,
    2. Machnik M,
    3. Troll M, et al

    . Larger gray matter volumes in neuropsychiatric long-COVID syndrome. Psychiatry Res 2022;317:114836 doi:10.1016/j.psychres.2022.114836 pmid:36087363

    CrossRefPubMed
37. 37.↵
    1. Lu Y,
    2. Li X,
    3. Geng D, et al

    . Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine 2020;25:100484 doi:10.1016/j.eclinm.2020.100484 pmid:32838240

    CrossRefPubMed
38. 38.↵
    1. Qin Y,
    2. Wu J,
    3. Chen T, et al

    . Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J Clin Invest 2021;131:e147329 doi:10.1172/JCI147329

    CrossRefPubMed
39. 39.↵
    1. Douaud G,
    2. Lee S,
    3. Alfaro-Almagro F, et al

    . SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022;604:697–707 doi:10.1038/s41586-022-04569-5 pmid:35255491

    CrossRefPubMed
40. 40.↵
    1. Davenport EM,
    2. Apkarian K,
    3. Whitlow CT, et al

    . Abnormalities in diffusional kurtosis metrics related to head impact exposure in a season of high school varsity football. J Neurotrauma 2016;33:2133–46 doi:10.1089/neu.2015.4267 pmid:27042763

    CrossRefPubMed
41. 41.↵
    1. Chung S,
    2. Chen J,
    3. Li T, et al

    . Investigating brain white matter in football players with and without concussion using a biophysical model from multishell diffusion MRI. AJNR Am J Neuroradiol 2022;43:823–28 doi:10.3174/ajnr.A7522 pmid:35589140

    Abstract/FREE Full Text
42. 42.↵
    1. Alves R,
    2. Henriques RN,
    3. Kerkelä L, et al

    . Correlation tensor MRI deciphers underlying kurtosis sources in stroke. Neuroimage 2022;247:118833 doi:10.1016/j.neuroimage.2021.118833 pmid:34929382

    CrossRefPubMed
43. 43.↵
    1. Wang JJ,
    2. Lin WY,
    3. Lu CS, et al

    . Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology 2011;261:210–17 doi:10.1148/radiol.11102277 pmid:21771952

    CrossRefPubMed
44. 44.↵
    1. Rong Y,
    2. Xu Z,
    3. Zhu Y, et al

    . Combination of quantitative susceptibility mapping and diffusion kurtosis imaging provides potential biomarkers for early-stage Parkinson’s disease. ACS Chem Neurosci 2022;13:2699–708 doi:10.1021/acschemneuro.2c00321 pmid:36047877

    CrossRefPubMed
45. 45.↵
    1. Shi W,
    2. Qu C,
    3. Wang X, et al

    . Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression. Eur J Radiology 2021;144:109941 doi:10.1016/j.ejrad.2021.109941 pmid:34735828

    CrossRefPubMed
46. 46.↵
    1. Budde MD,
    2. Frank JA

    . Neurite beading is sufficient to decrease the apparent diffusion coefficient after ischemic stroke. Proc Natl Acad Sci U S A 2010;107:14472–77 doi:10.1073/pnas.1004841107 pmid:20660718

    Abstract/FREE Full Text
47. 47.↵
    1. Raab P,
    2. Hattingen E,
    3. Franz K, et al

    . Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. Radiology 2010;254:876–81 doi:10.1148/radiol.09090819 pmid:20089718

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Steven AJ,
    2. Zhuo J,
    3. Melhem ER

    . Diffusion kurtosis imaging: an emerging technique for evaluating the microstructural environment of the brain. AJR Am J Roentgenol 2014;202:W26–33 doi:10.2214/AJR.13.11365 pmid:24370162

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Zhuo J,
    2. Xu S,
    3. Proctor JL, et al

    . Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury. NeuroImage 2012;59:467–77 doi:10.1016/j.neuroimage.2011.07.050 pmid:21835250

    CrossRefPubMed
50. 50.↵
    1. Thakur KT,
    2. Miller EH,
    3. Glendinning MD, et al

    . COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 2021;144:2696–708 doi:10.1093/brain/awab148 pmid:33856027

    CrossRefPubMed
51. 51.↵
    1. Matschke J,
    2. Lütgehetmann M,
    3. Hagel C, et al

    . Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020;19:919–29 doi:10.1016/S1474-4422(20)30308-2 pmid:33031735

    CrossRefPubMed
52. 52.↵
    1. Fernández-Castañeda A,
    2. Lu P,
    3. Geraghty AC, et al

    . Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 2022;185:2452–2468.e16 doi:10.1016/j.cell.2022.06.008 pmid:35768006

    CrossRefPubMed
53. 53.↵
    1. Benedetti F,
    2. Palladini M,
    3. Paolini M, et al

    . Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: a multimodal magnetic resonance imaging study. Brain Behav Immun Health 2021;18:100387 doi:10.1016/j.bbih.2021.100387 pmid:34746876

    CrossRefPubMed
54. 54.↵
    1. Petersen M,
    2. Nägele FL,
    3. Mayer C, et al

    . Brain imaging and neuropsychological assessment of individuals recovered from a mild to moderate SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2023;120:e2217232120 doi:10.1073/pnas.2217232120 pmid:37220275

    CrossRefPubMed
55. 55.↵
    1. Shan ZY,
    2. Kwiatek R,
    3. Burnet R, et al

    . Progressive brain changes in patients with chronic fatigue syndrome: a longitudinal MRI study. J Magn Reson Imaging 2016;44:1301–11 doi:10.1002/jmri.25283 pmid:27123773

    CrossRefPubMed
56. 56.↵
    1. Papadopoulou A,
    2. Müller-Lenke N,
    3. Naegelin Y, et al

    . Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Mult Scler 2013;19:1290–96 doi:10.1177/1352458513475490 pmid:23459568

    CrossRefPubMed
57. 57.↵
    1. Dowling JW,
    2. Forero A

    . Beyond good and evil: molecular mechanisms of type I and III IFN functions. J Immunol 2022;208:247–56 doi:10.4049/jimmunol.2100707 pmid:35017214

    Abstract/FREE Full Text
58. 58.↵
    1. Medana IM,
    2. Esiri MM

    . Axonal damage: a key predictor of outcome in human CNS diseases. Brain 2003;126:515–30 doi:10.1093/brain/awg061 pmid:12566274

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Mulero P,
    2. Midaglia L,
    3. Montalban X

    . Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018;11:1756286418773025 doi:10.1177/1756286418773025 pmid:29774057

    CrossRefPubMed
60. 60.↵
    1. Xu J,
    2. Cheng Y,
    3. Chai P, et al

    . White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. J Rheumatol 2010;37:974–86 doi:10.3899/jrheum.090967 pmid:20231206

    Abstract/FREE Full Text
61. 61.↵
    1. Blasko I,
    2. Hinterberger M,
    3. Kemmler G, et al

    . Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 2012;16:687–94 doi:10.1007/s12603-012-0051-y pmid:23076510

    CrossRefPubMed
62. 62.↵
    1. Mayer AR,
    2. Ling J,
    3. Mannell MV, et al

    . A prospective diffusion tensor imaging study in mild traumatic brain injury. Neurology 2010;74:643–50 doi:10.1212/WNL.0b013e3181d0ccdd pmid:20089939

    Abstract/FREE Full Text